key: cord-0708644-u3w6btpr
authors: Castaneda, G. E.; Lee, A. C.; Li, W. T.; Chen, C.; Chakladar, J.; Chang, E.; Ongkeko, W.
title: Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy and venous thromboembolism
date: 2020-09-02
journal: nan
DOI: 10.1101/2020.08.28.20184234
sha: 34b8fa2447628ad3e50351b05538dff4a670c5be
doc_id: 708644
cord_uid: u3w6btpr

As of 28 August 2020, there have been 5.88 million Coronavirus Disease 2019 (COVID-19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation that accompanies cardiovascular disease predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation in patients with cardiomyopathy, venous thromboembolism and COVID-19 patients by looking at immune-associated gene dysregulation, immune infiltration and dysregulated immunological pathways and gene signatures.

In December 2019, widespread infection by severe acute respiratory syndrome 31 coronavirus 2 (SARS-CoV-2), was reported in Wuhan, Hubei Province, China [1] . Since then, 32 SARS-CoV-2 has spread rapidly throughout China abnormalities, which may lead to increased risk of thromboembolic events [17] . In all, current 45

research suggests a link between cardiovascular disease and COVID-19. However, how 46 cardiovascular disease results in poorer COVID-19 prognosis and higher mortality rates remains 47 unclear. 48

Cardiomyopathy is a cardiovascular disease where the heart muscles become inflamed, 49 making it difficult for the heart to pump blood throughout the body. One of the most common forms 50 of cardiomyopathy is dilated cardiomyopathy (DCM), where the ventricles of the heart are 51

enlarged [18] . The primary cause of DCM is unclear. However, DCM can be caused by viral 52

infections that target the heart muscles and can thereby cause heart attacks or coronary artery 53 disease. When DCM is induced by a heart attack or coronary artery disease it is known as 54

ischemic cardiomyopathy (ICM). By promoting an inflammatory milieu and fibrosis, cytokines and 55

inflammasomes play a role in cardiomyopathy pathogenesis, which suggests a potential 56

connection between cardiomyopathy and COVID-19 [19] [20] [21] . 57 VTE includes both deep vein thrombosis (DVT), where a blood clot forms in a deep vein, 58

and pulmonary embolism (PE), where a clot dislodges and travels to the lungs via the 59 bloodstream, blocking pulmonary circulation. It is well-established that the immune system plays 60 a role in DVT pathogenesis, and restriction of venous blood flow leads to the recruitment of 61 neutrophils, monocytes and platelets [22] [23] [24] . Given that higher levels of monocytes and 62

neutrophils have been observed in COVID-19 patients requiring ICU hospitalization, it is possible 63 that such pre-existing immune dysregulation in COVID-19 VTE patients makes them more likely 64

to progress to severe disease [25] [26] [27] .

In this project, we aim to characterize dysregulation of the immune landscape in patients 66

with cardiomyopathy, with VTE and with COVID-19. We analyzed the expression of cytokine 67 genes and inflammasome-related genes using RNA-sequencing data obtained from COVID-19 68

and cardiomyopathy patients We also analyzed the extent of immune infiltration and the 69 enrichment of immunological pathways and signatures. By comparing these features of the genes dysregulated in COVID-19 are also dysregulated in either or both types of cardiomyopathy 93

( Figure 1A ). We grouped these genes into cytokine-related and inflammasome-related genes. 94

Cytokine-related genes that are dysregulated in both cardiomyopathy patients and COVID-19 95 patients include chemokines (CCL3, CCL4, CXCL4, etc), interleukins or interleukin receptors 96 (IL15, IL20RA, etc.), or genes in the TGFB family. Inflammasome-related genes include genes in 97 the caspase family (CASP2, CASP9, etc), MAPK-related genes, and NFkB regulators (IKBKG, 98 NFKBIA, etc.). IA gene dysregulation is very similar between dilated and ischemic 99 cardiomyopathies. We observed that a significant number of cytokines, interleukins, TGFB-100 related genes, and TNF-related genes were dysregulated in either types of cardiomyopathies but 101 not in COVID-19 ( Figure 1A ). 102 Interestingly, we found that most genes dysregulated in both COVID-19 and 109 cardiomyopathy, were dysregulated to a greater degree in COVID-19 samples than in 110 cardiomyopathy samples. This trend was observed for TGFB3, CCL4, IL15, and IL20RA in both 111

ischemic cardiomyopathy samples vs COVID-19 samples and dilated cardiomyopathy samples 112

vs. COVID-19 samples ( Figure 1B) . Furthermore, the expression of these dysregulated genes 113 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. . appeared to be very similarly dysregulated in COVID-19 samples and in corresponding healthy 114 samples, with similar levels of gene expression for individual patients in each group and a distinct 115 upregulation trend in COVID-19 samples ( Figure 1C ). In contrast, these genes' expression in 116 cardiomyopathy samples and corresponding healthy samples are only sometimes similar, without 117 overwhelming differences in expression levels between the two cohorts ( Figure 1C ). Therefore, 118

we believe that these dysregulated genes are dysregulated to a greater degree in COVID-19 than 119

in cardiomyopathy. 120

The inflammasome-associated genes dysregulated in both COVID-19 and cardiomyopathy are 121 upregulated in both conditions ( Figure 1C ), suggesting that COVID-19 and cardiomyopathy may 122 upregulate inflammation through similar pathways. 123 124

Using Cibersortx, we inferred the percent composition of 22 different immune cell types using the 126 gene expression profile of bulk RNA-sequencing data. We discovered that the levels of T cells 127

and B cells were unchanged in healthy vs. COVID-19 patients ( Figure 1D ). The most noticeable 128 change in immune cell abundance occurs in macrophages for COVID-19 patients, where M0 129 macrophages levels were dramatically reduced, and M1 and M2 macrophages levels were slightly 130 increased ( Figure 1D ). Both ischemic and dilated cardiomyopathy elicited greater immune cell 131

abundance changes than COVID-19 did, with the changes being more pronounced for ischemic 132 myocardiopathy. The levels of M1 and M2 macrophages also increased in ischemic 133 myocardiopathy, similar to what was observed for COVID-19 ( Figure 1D ). The levels of T and B 134

cell subtypes changed more dramatically in ischemic and dilated myocardiopathy than in COVID-135

19. In summary, the levels of inflammatory macrophages increased for both cardiomyopathy and 136

COVID-19 patients, while the levels of other immune cell types did not correlate between the two 137

conditions. 138

cardiomyopathy 140

To obtain a deeper understanding of the functions of the dysregulated genes in COVID-19 and 141 cardiomyopathy, we correlated IA gene expression to the dysregulation of canonical biological 142 pathways, obtained from the Molecular Signatures Database (MsigDB) [28] . We analyzed genes 143 that are dysregulated in both COVID-19 and cardiomyopathy to assess if they may dysregulate 144 the common pathways in the two conditions. IRAK2, upregulated in both COVID-19 and ischemic 145 cardiomyopathy, was associated with the upregulation of the FCER1 and TP63 pathways, both 146

of which are associated with inflammation and immune activation ( Figure 2A) IA genes and pro-inflammatory pathways and signatures, we hypothesize that CYLD may be 155 expressed as a response to attenuate excessive inflammation. We found that the overwhelming 156 majority of pathways that correlated with dysregulated genes in both COVID-19 and dilated 157 cardiomyopathy is associated with CYLD, and these pathways are primarily pro-plotting, pro-cell 158 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint aggregation, and pro-inflammation ( Figure 2B ), which reinforces the possibility that CYLD is 159 released in response to inflammation. 160 cardiomyopathy, the similarities between COVID-19 and VTE are much less-pronounced. We 172 identified two cytokine-associated genes that were dysregulated in both COVID-19 and single 173 VTE (CCL4 and CD40), and one cytokine-associated gene dysregulated in both COVID-19 and 174 recurrent VTE (CCL4) ( Figure 3A ). CCL4 is a recruiter of immune cells, including macrophages, 175 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint monocytes, and T-cells [36] , suggesting that both COVID-19 and VTE may experience increased 176 recruitment of inflammatory immune cells. The upregulation of CCL4 is much greater in COVID-177

19 than in VTE, however ( Figure 3B ). 178

Two inflammasome-related genes were found to be dysregulated in VTE and COVID-19, 179

including BCL2L1 and CASP4. Both single and recurrent VTE share the same set of dysregulated 180

inflammasome-related genes with COVID-19. BCL2L1 is known to be highly upregulated in 181

inflamed tissue [37] , and it is upregulated in COVID-19 and both single and recurrent VTE ( Figure  182 3C). CASP4 directs the noncanonical upregulation of inflammasomes [38] . Interestingly, it is 183 upregulated in both COVID-19 and recurrent VTE but downregulated in single VTE ( Figure 3C ), 184

which potentially suggests that the gene could contribute to the development of recurrent VTE. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint

Comparing immune cell population abundance between COVID-19 and VTE patients, we found 194 that naïve B-cells were dramatically reduced in abundance in VTE patients, which is accompanied 195 by a slight increase in activated plasma B cells ( Figure 3D ). This may be a sign of adaptive 196 immune activation. 197

We adopted a similar approach as described for COVID-19 vs. cardiomyopathy to examine 200 canonical pathways correlated with dysregulated genes in both COVID-19 and VTE. BCL2L1 and 201

CASP4 are the only genes dysregulated in both COVID-19 and VTE and also correlated with the 202 same pathways in both patient cohorts ( Figure 4A,B) . BCL2L1 is upregulated in COVID-19 and 203

both VTE cohorts ( Figure 4C ). However, the direction of correlation to pathways was the complete 204 opposite between COVID-19 and recurrent VTE ( Figure 4D, E) . The high strength of correlation 205

for each cohort suggests that BCL2L1 is involved in both COVID-19 and recurrent VTE but may 206 function in opposite ways. On the other hand, CASP4 expression was correlated with over 10 207 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . pathways in the same direction for both COVID-19 and recurrent VTE ( Figure 4D ). It is also 214 upregulated in both COVID-19 and recurrent VTE ( Figure 4C ). The pathways correlated with 215 CASP4 ranges from immune related (antigen processing and cross presentation) to general 216 metabolism-related (ABC transporter, oxidative phosphorylation). Therefore, while it is likely that 217 CASP4 functions similarly in COVID-19 and recurrent VTE. The precise role of CASP4 requires 218 further investigation. 219 220

In this project, we characterized the immune landscape of cardiomyopathy patients, VTE patients, 223

and COVID-19 patients, drawing parallels between COVID-19 and immune dysregulation 224 mediated by cardiovascular disease. Exploring the immune-association gene dysregulation landscape relationship between VTE and 261 COVID-19 revealed overlapping differentially expression of CCL4, CD40, BCL2L1 and CASP4. 262 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. severity and mortality may be meaningful, and can offer greater insight into COVID-19 immune 296

dysregulation. However, we recognize our study has several limitations. We had limited COVID-297

19 platelet data, specifically normal patients. Thus, our differential expression analysis may have 298 been impacted, and the statistical power of our analysis is reduced. However, the direction of 299 dysregulation of many of the genes we identified were consistent with existing literature. 300

Additionally, we used platelet data, instead of blood samples. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. The CIBERSORTx algorithm was used to deconvolute RNA-sequencing data to estimate CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint

Clinical characteristics 363 of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical findings in a group of patients infected with the 366 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case studies

Epidemiological and clinical characteristics of 99 cases of 369 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 373

COVID -19 acute respiratory distress syndrome ( ARDS ): clinical 375 features and differences from typical pre-COVID -19 ARDS

Prevalence of comorbidities and its effects in patients infected 378 with SARS-CoV-2: a systematic review and meta-analysis

Impact of cerebrovascular and 381 cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-382 analysis, and meta-regression

Predictors of mortality in hospitalized COVID-19 patients: A 385 systematic review and meta-analysis

Association of cardiac injury with mortality in hospitalized patients with COVID-387 19 in Wuhan, China

Cardiovascular implications of fatal outcomes of patients with coronavirus 389 disease 2019 (COVID-19)

Characteristics and clinical significance of myocardial injury in patients with 392 severe coronavirus disease 2019

The trinity of COVID-19: 394 immunity, inflammation and intervention

In the eye of the COVID-19 cytokine storm

Thromboinflammation and the hypercoagulability of 398 COVID-19

Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-405

Inflammatory Marker in Cardiovascular Diseases

NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis 408 of non-ischemic dilated cardiomyopathy

Monocytes, neutrophils, and platelets cooperate to initiate and propagate 411 venous thrombosis in mice in vivo

Neutrophil extracellular traps promote deep vein thrombosis in mice

Neutrophil extracellular trap (NET) impact on deep vein thrombosis

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in 417 severe COVID-19 patients

COVID-19 infection induces readily detectable morphological and 419 inflammation-related phenotypic changes in peripheral blood monocytes, the severity of 420 which correlate with patient outcome

Clinical characteristics of 138 hospitalized 423 patients with 2019 novel coronavirus-infected pneumonia in Wuhan

The role of FcεRI expressed in dendritic cells and monocytes

Regulation of the interferon-gamma (IFN-γ) pathway 430 by p63 and Δ133p53 isoform in different breast cancer subtypes

IRAK-2 Participates in Multiple Toll-like Receptor 433

Signaling Pathways to NFκB via Activation of TRAF6 Ubiquitination

Incoming RNA virus nucleocapsids containing a 436 5'-triphosphorylated genome activate RIG-I and antiviral signaling

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the 439 Prostate and Prostate Cancer

Eicosanoids in Mammals. Comprehensive Natural Products Chemistry

Deubiquitination of NLRP6 444 inflammasome by Cyld critically regulates intestinal inflammation

Chemokines 447 enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell 448 interaction

Persistent Inflammatory Pathways Associated with Early

Onset Myocardial Infarction in a Medicated Multiethnic Hawaiian Cohort

Collman 454 RG, Shin S: Human caspase-4 mediates noncanonical inflammasome activation 455 against gram-negative bacterial pathogens

Transcriptomic characteristics of bronchoalveolar lavage fluid 458 and peripheral blood mononuclear cells in COVID-19 patients

Synergy of Interleukin (IL)-5 and 461 IL-18 in eosinophil mediated pathogenesis of allergic diseases

Functions of IL-15 in anti-viral immunity: multiplicity and 464 variety

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Pathological findings of COVID-19 associated with acute respiratory distress 468 syndrome

Activated T Lymphocytes are Essential Drivers of 470

Dysfunctional and Proinflammatory Regulatory T-473

Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy

T-cell recruitment to the heart: friendly guests or 476 unwelcome visitors?

Pathological inflammation in patients with COVID-19: a key role for 479 monocytes and macrophages

Transcriptomic characteristics of 483 bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Emerging role of chemokine CC motif ligand 4 related 486 mechanisms in diabetes mellitus and cardiovascular disease: friends or foes

CASP4 gene silencing in epithelial cancer 490 cells leads to impairment of cell migration, cell-matrix adhesion and tissue 491 invasion

COVID-19 and Cardiovascular Disease

Potential effects of 495 coronaviruses on the cardiovascular system: a review

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.28.20184234 doi: medRxiv preprint